Cellular Biomedicine Group's Price has increased by 100.00% In the last year, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $0.00 – an increase of 100.00%. For the next eleven years, the forecast is for Fair Value to grow by 100.00%.

2020 Fair Value Forecast

$0.00

2021 Fair Value Forecast

$0.00

2022 Fair Value Forecast

$0.00

2023 Fair Value Forecast

$0.00

2024 Fair Value Forecast

$0.00

2025 Fair Value Forecast

$0.00

2026 Fair Value Forecast

$0.00

2027 Fair Value Forecast

$0.00

2028 Fair Value Forecast

$0.00

2029 Fair Value Forecast

$0.00

2030 Fair Value Forecast

$0.00

Cellular Biomedicine Group Revenue Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group's Revenue has increased by 54.55% In the last year, going from $220.00k to $340.00k. In the next year, analysts expect Revenue to reach $459.99k – an increase of 35.29%. For the next eleven years, the forecast is for Revenue to grow by 710.68%.

2020 Rev Forecast

$459.99k

2021 Rev Forecast

$594.07k

2022 Rev Forecast

$760.29k

2023 Rev Forecast

$938.99k

2024 Rev Forecast

$0.00B

2025 Rev Forecast

$0.00B

2026 Rev Forecast

$0.00B

2027 Rev Forecast

$0.00B

2028 Rev Forecast

$0.00B

2029 Rev Forecast

$0.00B

2030 Rev Forecast

$0.00B

Cellular Biomedicine Group Dividend per Share Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's Free Cash Flow has grown from $-31.70M to $-50.32M – a 58.74% increase. In the following year, the 0 analysts surveyed believe that Cellular Biomedicine Group's Free Cash Flow will decrease by 37.00%, reaching $-31.70M. According to professionals, by 2030, Cellular Biomedicine Group's Free Cash Flow will have decreased by 18.43%, falling down to $-41.05M.

2020 FCF Forecast

$-31701600.00

2021 FCF Forecast

$-40203969.12

2022 FCF Forecast

$-40281696.79

2023 FCF Forecast

$-45302138.94

2024 FCF Forecast

$-40406487.79

2025 FCF Forecast

$-40520972.84

2026 FCF Forecast

$-40623625.97

2027 FCF Forecast

$-42193052.05

2028 FCF Forecast

$-41595317.15

2029 FCF Forecast

$-41244529.97

2030 FCF Forecast

$-41047931.05

Cellular Biomedicine Group Net Income Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's Net Income has grown by 28.32%, from $-38.95M to $-49.98M. For the following year, the 0 analysts predict that Cellular Biomedicine Group's Net Income will drop by 22.07%, reaching $-38.95M. In 2030, the professionals' prediction is that CBMG's Net Income will decrease by 12.87%, reaching $-43.55M.

2020 NI Forecast

$-38949414.00

2021 NI Forecast

$-43437684.81

2022 NI Forecast

$-42846932.29

2023 NI Forecast

$-45613415.89

2024 NI Forecast

$-43329704.20

2025 NI Forecast

$-43413474.96

2026 NI Forecast

$-43270210.49

2027 NI Forecast

$-44050516.62

2028 NI Forecast

$-43811175.48

2029 NI Forecast

$-43681202.33

2030 NI Forecast

$-43547246.64

Cellular Biomedicine Group EBITDA Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's EBITDA has grown by 39.37%, rising from $-32.54M to $-45.35M. The next year, 0 experts forecast that Cellular Biomedicine Group's EBITDA will decrease by 28.25%, reaching $-32.54M. In 2030, professionals predict that Cellular Biomedicine Group's EBITDA will decrease by 15.58%, reaching $-38.29M.

2020 EBITDA Forecast

$-32538625.00

2021 EBITDA Forecast

$-38014875.59

2022 EBITDA Forecast

$-37597979.12

2023 EBITDA Forecast

$-40865243.50

2024 EBITDA Forecast

$-37963811.22

2025 EBITDA Forecast

$-38058720.74

2026 EBITDA Forecast

$-37981334.68

2027 EBITDA Forecast

$-38942262.45

2028 EBITDA Forecast

$-38615147.44

2029 EBITDA Forecast

$-38432369.08

2030 EBITDA Forecast

$-38286326.07

Cellular Biomedicine Group EBIT Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's EBIT has grown by 35.65%, rising from $-37.59M to $-50.99M. According to the 0 analysts polled, in the next year, Cellular Biomedicine Group's EBIT will fall by 26.28%, reaching $-37.59M. By 2030, professionals believe that Cellular Biomedicine Group's EBIT will have decreased by 14.76%, falling to $-43.46M.

2020 EBIT Forecast

$-37589828.00

2021 EBIT Forecast

$-43230808.19

2022 EBIT Forecast

$-42700510.27

2023 EBIT Forecast

$-46093777.49

2024 EBIT Forecast

$-43148385.11

2025 EBIT Forecast

$-43250502.95

2026 EBIT Forecast

$-43139493.33

2027 EBIT Forecast

$-44124511.76

2028 EBIT Forecast

$-43799461.19

2029 EBIT Forecast

$-43619883.40

2030 EBIT Forecast

$-43462851.82

Cellular Biomedicine Group EPS Price Prediction Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group's EPS has increased by 49.43% In the last year, going from $-1.76 to $-2.63. In the following year, 0 experts forecast that Cellular Biomedicine Group's EPS will decrease by 33.08%, to $-1.76. In 2030, professionals predict that Cellular Biomedicine Group's EPS will decrease by 17.31%, to $-2.17.

2020 EPS Forecast

$-1.76

2021 EPS Forecast

$-2.15

2022 EPS Forecast

$-2.13

2023 EPS Forecast

$-2.36

2024 EPS Forecast

$-2.15

2025 EPS Forecast

$-2.15